Connect with us

Local Media

[Axios] A Banner Year for Prescription Drugs Brings Cost Concerns

January 6, 2023 – Axios recently published an article where Associate Professor of Markets, Public Policy, and Law, Rena Conti discusses the prescription drug approvals expected in 2023, and the already-contentious debates around affordability and equity.

Rena Conti

Published

on

January 6, 2023

Axios recently published an article where Associate Professor of Markets, Public Policy, and Law, Rena Conti discusses the prescription drug approvals expected in 2023, and the already-contentious debates around affordability and equity.

Despite their success in treating conditions like Alzheimer’s or sickle cell disease, the high prices of these drugs cause dilemmas for insurers, governments, and patients. Conti elaborates on this debate by stating, “they will create choices that need to be made and they will also create potential burdens, particularly on the most vulnerable, on people who are the least well-insured and people who live in states or happen to have insurance coverage that is the least generous.”

New discussions about how to pay for some drugs may result from the upcoming drug approvals.

Rena M. Conti is an Associate Professor at the Boston University Questrom School of Business. From 2006 through June 2018, Professor Conti was an Associate Professor of Health Economics and Policy at the University of Chicago Medical School and the Harris School of Public Policy. She is a health economist and her research focuses on the organization, financing and regulation of medical care. She has written extensively on the pricing, demand and supply of prescription drugs.

Suggest Topic
X